Koji KONO

Dr Koji Kono has been striving to develop immunotherapies for cancer patients, in addition to his practice as an upper GI surgeon. His approach is based on a translational research from the viewpoint of both surgical oncology and tumor immunology. His main research themes are to develop cancer vaccine with immunogenic peptides and to establish a novel NK cell therapy against gastric and esophageal cancer.

Our translational research is based on viewpoints of both surgical oncology and tumor immunology. Our main research themes are as follows:

  • To identify immunogenic peptides from novel Cancer-Testis antigens applicable to cancer vaccine
  • To elucidate mechanisms underlying chemoradiation can induce the immunogenic tumor cell death, leading to tumor-specific immune responses
  • To develop a novel NK cell therapy to enhance an ADCC activity against GI cancer
  • To analyze the HER-family signaling in GI cancer

During the next 5 years, we wish to pursue 2 major directions for our translational research. First is antigen-specific immunotherapy based on cancer vaccines with multiple peptides. Previously, we identified immunogenic epitopes of peptides preferentially expressed in gastric and esophageal cancer cells and developed clinical trials which yielded encouraging results, leading to the design of a phase III trial currently ongoing. These vaccines were prepared to match a common HLA type among Japanese, HLA-A2402. However, Chinese Singaporean most frequently express the HLA-A1101 type. Thus, our aim is to use the protocols that we have successfully established and to generate vaccines matching the HLA-A1101 type. Once we identify the immunogenic peptides, we can apply for the cancer vaccine, in particular as a combination with chemoradiation, since we recently reported that chemoradiation can induce the immunogenic tumor cell death with tumor-specific immune responses.

The second major direction of my research centers on the adoptive transfer of ex vivo expanded NK cells. In preliminary studies, we demonstrated that NK cells expanded with the unique method (“super NK cells”) are much more cytotoxic against gastric cancer cells than resting or IL-2 activated NK cells. We also found that these NK cells mediated superior antibody-dependent cell cytotoxicity in the presence of Herceptin and that NK cells from gastric cancer patients could be expanded as well as those of healthy donors. Based on the promising results, we will initiate a phase I clinical trial of adoptive transfer of autologous super NK cells for gastric cancer, to evaluate safety, feasibility as well as immunological response.

kokolab4

Selected Publications:

  1. Yu-Hsiang Chang, John Connolly, Noriko Shimasaki, Kosaku Mimura, Koji Kono, Dario Campana. A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells. Cancer Research 2013 Mar 15;73(6):1777-86
  2. Yoshiyuki Suzuki, Kousaku Mimura, Yuya Yoshimoto, Mitsuaki Watanabe,Yu Ohkubo, Shinichirou Izawa, Kazutoshi Murata, Hideki Fujii, Takashi Nakano, and Koji Kono. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Research 2012 Aug 15;72(16):3967-76.
  3. Koji Kono, Hisae Iinuma, Yasunori Akutsu, Hiroaki Tanaka, Naoko Hayashi, Yasuto Uchikado, Tsuyoshi Noguchi, Hideki Fujii, Kota Okinaka, Ryoji Fukushima, Hisahiro Matsubara, Kousei Hirakawa, Hideo Baba, Shoji Natsugoe, Seigou Kitano, Koji Yoshida, Takuya Tsunoda, and Yusuke Nakamura. Multicenter, Phase II clinical trial of Cancer Vaccination with Multiple Peptides derived from Novel Cancer-Testis Antigens in Advanced Esophageal cancer. Journal of Translational Medicine. 2012 Jul 9;10:141
  4. Kousaku Mimura, Koji Kono#, Takanori Maruyama, Mitsuaki Watanabe, Shinichiro Izawa, Shugo Shiba, Yoshiki Mizukami, Yoshihiko Kawaguchi, Masayuki Inoue, Tetsuo Kono, and Hideki Fujii. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody dependent cellular cytotoxicity of EGFR and HER2 over-expressing esophageal cancer cell lines. International Journal of Cancer. 2011 15;129:2408-2416.(#, corresponding author)
  5. Yoshiki Mizukami, Koji Kono#, Yoshihiko Kawaguchi, Hidenori Akaike,Kazuyasu Kamimura, Hidemitsu Sugai, and Hideki Fujii. CCL17 and CCL22 chemokines within Tumor Microenvironment are related to Accumulation of Foxp3+ Regulatory T cells in Gastric Cancer. International Journal of Cancer 2008;122:2286-2293 (#, corresponding author)
  6. Kousaku Mimura, Koji Kono#, Mitsuhiko Hanawa, Mirei Kanzaki, Atsuhito Nakao, Akishi Ooi, and Hideki Fujii. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clinical Cancer Research 2005;11:4898-4904. (#, corresponding author)
  7. Koji Kono, Eiji Sato, Hirofumi Naganuma, Akihiro Takahashi, Kousaku Mimura, Hideaki Nukui and Hideki Fujii. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific CTLs. Clinical Cancer Research 2004;10:2538-2544.
  8. Koji Kono, Akihiro Takahashi, Hidemitsu Sugai, Hideki Fujii, A. Raja Choudhury, Rolf Kiessling, and Yoshiro Matsumoto. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clinical Cancer Research 2002;8:3394-3400.
  9. Koji Kono, Akihiro Takahashi, Fumiko Ichihara, Hideki Amemiya, Hidehiko Iizuka, Hideki Fujii, Takayoshi Sekikawa, and Yoshiro Matsumoto. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: A randomized trial. Clinical Cancer Research 2002;8:1767-1771.
  10. Koji Kono, Akihiro Takahashi, Fumiko Ichihara, Hidemitsu Sugai, Hideki Fujii, and Yoshiro Matsumoto. Impaired antibody-dependent cellular cytotoxicity mediated by Herceptin in patients with gastric cancer. Cancer Research 2002;62:5813-5817.
Name Koji KONO
Affiliations Principle Associate, Cancer Science Institute of Singapore, NUS
Associate Professor, Department of Surgery, National University of Singapore (NUS)
Visiting Professor, First Department of Surgery, University of Yamanashi, Japan
Email surkoji[at]nus.edu.sg

Education

Institute Degree (if applicable) Year(s)
Karolinska Institute (Stockholm, Sweden) Ph.D 1997
Yamanashi Medical University (Yamanashi, Japan) Ph.D 1996
Yamanashi Medical University (Yamanashi, Japan) M.D 1987

Professional Experience

Principle Associate, Cancer Science Institute of Singapore, NUS 2013 – present
Associate Professor, Department of Surgery, NUS 2011 – present
Associate Professor, 1st Dept. of Surgery, University of Yamanashi, Japan 2003 – 2011
Assistant Professor, 1st Dept. of Surgery, University of Yamanashi, Japan 1996 – 2003
Guest Researcher, Microbiology and Tumor Biology Center, Karolinska Institute, Sweden 1994 – 1996
Surgeon, Senior Resident and Resident, 1st Dept. of Surgery, Yamanashi Medical University, Japan 1987 – 1994

Kosaku MIMURA

MD, PhD
Senior Research Fellow

Development of immunotherapy with cytotoxic T lymphocytes and Natural Killer cells against gastrointestinal tract cancer. To clarify effects of HER2 related signaling on MHC class I expression on cancer cells.

Kensuke SHIRAISHI

Research Associate

To elucidate mechanisms underlying the immunogenic tumor cell death induced by chemoradiotherapy.

LIM Kee Siang

PhD Student

Focus on adoptive immunotherapy using super nature killer cells against gastro-esophageal cancers and head and neck cancers.